Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 239

The DOI matches its Crossref record.

Prevalence of HIV‐1 Drug Resistance after Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South Africa

Open access
Marconi, Vincent C., Sunpath, Henry, Lu, Zhigang, Gordon, Michelle, Koranteng‐Apeagyei, Kofi, Hampton, Jane, Carpenter, Steve, Giddy, Janet, Ross, Douglas, Holst, Helga, Losina, Elena, Walker, Bruce D., Kuritzkes, Daniel R., South Africa Resistance Cohort Study Team·2008·Clinical Infectious Diseases

Abstract

BACKGROUND: Emergence of human immunodeficiency virus type 1 (HIV-1) drug resistance may limit the benefits of antiretroviral therapy in resource-limited settings. The prevalence of resistance was assessed among patients from KwaZulu Natal, South Africa, following failure of their first highly active antiretroviral therapy (HAART) regimen. METHODS: Genotypic resistance testing was performed on plasma virus samples from patients who experienced virologic failure of their first HAART regimen at 2 clinics in KwaZulu Natal. Clinical and demographic data were obtained from medical records. Regression analysis was performed to determine factors associated with > or =1 significant drug resistance mutation. RESULTS: From January 2005 through August 2006, a total of 124 antiretroviral-treated adults who experienced virologic failure were enrolled. The predominant subtype was HIV-1C. Virus samples from 83.5% of participants carried > or =1 significant drug resistance mutation. Dual-class drug-resistant virus was present in 64.3% of participants, and 2.6% had virus with triple-class drug resistance. The most common mutation was M184V/I (64.3% of patients); K103N was present in virus from 51.3%, and V106M was present in virus from 19.1%. Thymidine analog resistance mutations were found in virus from 32.2% of patients, and protease resistance mutations were found in virus from 4.4%. CONCLUSIONS: Antiretroviral drug-resistant virus was detected in >80% of South African patients who experienced failure of a first HAART regimen. Patterns of drug resistance reflected drugs used in first-line regimens and viral subtype. Continued surveillance of resistance patterns is warranted to guide selection of second-line regimens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/587109

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 239

Metadata

Authors
Marconi, V. C., Sunpath, H., Lu, Z., Gordon, M., Koranteng‐Apeagyei, K., Hampton, J., Carpenter, S., Giddy, J., Ross, D., Holst, H., Losina, E., Walker, B. D., Kuritzkes, D. R., & South Africa Resistance Cohort Study Team
Venue
Clinical Infectious Diseases
Published
2008-05-15
Volume
46
Issue
10
Pages
1589-1597
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2102741140
Cited by
239
References
0
FWCI
18.25
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevalence of HIV‐1 Drug Resistance after Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South Africa. https://app.cochat.ai/papers/10.1086/587109
The paper
Marconi, V. C., Sunpath, H., Lu, Z., Gordon, M., Koranteng‐Apeagyei, K., Hampton, J., Carpenter, S., Giddy, J., Ross, D., Holst, H., Losina, E., Walker, B. D., Kuritzkes, D. R., & South Africa Resistance Cohort Study Team. (2008). Prevalence of HIV‐1 Drug Resistance after Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South Africa. Clinical Infectious Diseases. https://doi.org/10.1086/587109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.